Fig. 1From: Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysisSource studies for the pooled analysis. Post-treatment follow-up and pre-treatment baseline assessments were available in TEMPO 2:4, 3:4, and 4:4 and were used as off-treatment assessments as appropriate. SOC, standard of care management not including tolvaptan treatment; TOL, tolvaptanBack to article page